• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives

    9/8/25 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email

    CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business ("Wellspect"), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportunities for Wellspect, including a sale of the business. The Company conducted broad outreach, including engaging with multiple parties regarding their interest in Wellspect.

    Following extensive review and deliberation, Dentsply Sirona determined that retaining Wellspect as a subsidiary within its portfolio will create more value for Dentsply Sirona stockholders than the other alternatives available to the Company.

    "We are committed to improving patient outcomes and driving long-term value for Dentsply Sirona customers, employees and stockholders. To that end, after executing a comprehensive review of strategic alternatives for Wellspect, we are confident that retaining the business will deliver greater financial and strategic benefits to stockholders than the other options available," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "Wellspect is a category leader in the global continence care market with a high-quality product pipeline, strong cash flow generation and significant untapped market potential. The recent investments we've made in Wellspect are generating results, and we believe that the business will continue to play an important role in our strategy to deliver durable, profitable growth across the entire Dentsply Sirona portfolio."

    Scavilla continued, "Since stepping into the CEO role in August, I have met with investors, customers, partners, employees and other stakeholders to understand their perspectives on our business. While it's clear to me from those discussions that our foundation is solid, it is evident that we need to do more to improve the customer experience and move faster as an organization while delivering stronger financial and operational performance. I look forward to sharing more about our strategic priorities and future growth plans in the months ahead."

    Wellspect is a leading provider of bladder and bowel care products with an over 40-year history. Through its comprehensive portfolio of products and accessories from trusted brands like LoFric® and Navina™, Wellspect has delivered organic sales growth in recent years, including mid-single digit growth in 2024. Wellspect is well-positioned in the large and growing continence care space, which has an estimated $2 billion addressable market.

    About Dentsply Sirona

    Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

    Contact Information

    Investors:

    Wade Moody

    Senior Manager, Investor Relations

    [email protected]

    Press:

    Marion Par-Weixlberger

    Vice President, Public Relations & Corporate Communications

    +43 676 848414588

    [email protected]

    Forward-Looking Statements and Associated Risks

    All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.



    Primary Logo

    Get the next $XRAY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    11/7/2024Outperform → Market Perform
    Leerink Partners
    10/25/2024$34.00 → $29.00Buy
    Needham
    More analyst ratings

    $XRAY
    SEC Filings

    View All

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    9/8/25 8:33:06 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DENTSPLY SIRONA Inc.

    10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    8/7/25 9:18:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

    8/7/25 7:13:57 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, CEO & Member of BOD Scavilla Daniel T

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    8/12/25 5:25:20 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T was granted 3,858 shares, gifted 24,047 shares and received a gift of 24,047 shares, decreasing direct ownership by 20% to 82,301 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    8/12/25 5:22:54 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SVP, CHRO Frohning Andrea L. covered exercise/tax liability with 788 shares, decreasing direct ownership by 2% to 33,253 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    8/12/25 4:30:55 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives

    CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business ("Wellspect"), which was announced in February 2025. As a part of its review process, Dentsply Sirona considered a range of potential opportunities for Wellspect, including a sale of the business. The Company conducted broad outreach, including engaging with multiple parties regarding their interest in Wellspect. Following extensive review and deliberation, Dentsply Sirona determined that retaining Wellspect as a subsidiary within its portfoli

    9/8/25 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Participate in Upcoming Investor Conferences

    CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its participation at upcoming conferences. Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 2:35 pm ETBaird Global Healthcare Conference on September 9, 2025, at 1:25 pm ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, w

    8/26/25 4:30:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Reports Second Quarter 2025 Results

    Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impactGAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52Executed $550 million debt offeringReaffirmed FY25 outlookLeadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the second quarter of 2025. Second quarter net sales of $936 million dec

    8/7/25 6:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dentsply Sirona downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

    4/15/25 9:24:19 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona downgraded by Needham

    Needham downgraded Dentsply Sirona from Buy to Hold

    3/13/25 7:58:34 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Wells Fargo initiated coverage on Dentsply Sirona with a new price target

    Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00

    2/14/25 7:09:40 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

    CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

    5/29/25 4:30:00 PM ET
    $MTX
    $SMG
    $XRAY
    Major Chemicals
    Basic Materials
    Agricultural Chemicals
    Industrials

    Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

    CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

    3/17/25 8:45:57 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/12/24 4:23:31 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer

    CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025.  Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two

    7/21/25 8:30:00 AM ET
    $GMED
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona to Host Second Quarter Conference Call on August 7th

    CHARLOTTE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 7, 2025, at 8:30 am ET to review its financial results for the second quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at h

    7/10/25 8:30:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Declares Quarterly Cash Dividend

    CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

    5/27/25 4:15:00 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/25 6:33:03 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

    4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/29/25 6:14:01 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    11/18/24 4:16:34 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care